| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 04/10/2003 | US20030069425 Substituted pyrimidine compounds and methods of use |
| 04/10/2003 | US20030069423 Novel processes for the preparation of adenosine compounds and intermediates thereto |
| 04/10/2003 | US20030069406 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of blood disorders |
| 04/10/2003 | US20030069312 Nitromethyl ketones, process for preparing them and compositions containing them |
| 04/10/2003 | US20030069308 Antidiabetic agents |
| 04/10/2003 | US20030069297 4-aryl substituted indolinones |
| 04/10/2003 | US20030069294 Alpha-substituted carboxylic acid derivatives |
| 04/10/2003 | US20030069290 Substituted-heteroaryl-7-aza[2.2.1] bycycloheptanes for the treatment of desease |
| 04/10/2003 | US20030069287 Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors |
| 04/10/2003 | US20030069278 Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| 04/10/2003 | US20030069273 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
| 04/10/2003 | US20030069254 New arylsulfonyl derivatives with 5-HT6 receptor affinity |
| 04/10/2003 | US20030069249 Analgesics; central nervous system disorders |
| 04/10/2003 | US20030069246 Central nervous system disorders; psychological disorders; cardiovascular disorders |
| 04/10/2003 | US20030069245 Aids therapy |
| 04/10/2003 | US20030069243 Novel substituted imidazole compounds |
| 04/10/2003 | US20030069221 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 04/10/2003 | US20030069210 Especially imidazolyl- or 1,2,4-triazolyl- pyrimidine derivatives |
| 04/10/2003 | US20030069205 Anionic polymers including dermatan sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate, heparin, dextran sulfate, pentosan polysulfate, hyaluronic acid and alginate. |
| 04/10/2003 | US20030069201 Methods of using BCL-2 for the therapeutic treatment and prevention of diseases |
| 04/10/2003 | US20030069192 May be administered along with Rutin, a Rutin congener and/or a Rutin derivative. |
| 04/10/2003 | US20030069186 Chimeric natriuretic peptides |
| 04/10/2003 | US20030069181 Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| 04/10/2003 | US20030068429 Inulin products with improved nutritional properties |
| 04/10/2003 | US20030068361 For treating hyperglycemia and related disorders |
| 04/10/2003 | CA2462795A1 Secreted proteins |
| 04/10/2003 | CA2462419A1 N-heterocyclyl hydrazides as neurotrophic agents |
| 04/10/2003 | CA2462112A1 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 04/10/2003 | CA2462030A1 3-`hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7,8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors |
| 04/10/2003 | CA2461606A1 Nonhuman mammal model of autoimmune disease having ox40l gene transferred thereinto |
| 04/10/2003 | CA2461586A1 Compounds for the reduction of excessive food intake |
| 04/10/2003 | CA2461560A1 Inhibition of neonatal hyperbilirubinemia in breast fed infants |
| 04/10/2003 | CA2460916A1 Methods and compositions for modulating interleukin-21 receptor activity |
| 04/10/2003 | CA2460594A1 Mch receptor antagonists |
| 04/10/2003 | CA2459825A1 Compounds useful as reversible inhibitors of cysteine proteases |
| 04/10/2003 | CA2458343A1 Pharmaceutical combinations of pde-v inhibitors and other agents |
| 04/10/2003 | CA2455389A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 04/10/2003 | CA2455225A1 Novel proteins and nucleic acids encoding same |
| 04/10/2003 | CA2453343A1 Tetracyclic indole derivatives as 5-ht receptor ligands |
| 04/10/2003 | CA2430328A1 Receptor antagonist |
| 04/10/2003 | CA2425361A1 Pharmaceutical composition for promoting a recovery from stress and novel tricholoma matsutake strain |
| 04/09/2003 | EP1300404A1 Obesity inhibitory materials |
| 04/09/2003 | EP1300394A1 Method for the production of a water-dispersible formulation containing carotenoids |
| 04/09/2003 | EP1300147A1 Purine compounds and adenosine A2 receptor antagonist as preventive or therapeutic agent for diabetes mellitus |
| 04/09/2003 | EP1300142A1 Hypoglycemics |
| 04/09/2003 | EP1299545A2 Drug metabolizing enzymes |
| 04/09/2003 | EP1299542A2 Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
| 04/09/2003 | EP1299538A2 Secreted proteins |
| 04/09/2003 | EP1299424A1 COLD WATER SOLUBLE $g(b)-GLUCAN PRODUCT AND PROCESS FOR PREPARING THE SAME |
| 04/09/2003 | EP1299421A2 Antibodies to human mcp-1 |
| 04/09/2003 | EP1299418A1 Insulin derivatives and synthesis thereof |
| 04/09/2003 | EP1299412A2 Protein modification and maintenance molecules |
| 04/09/2003 | EP1299410A2 GFR alpha1-RET SPECIFIC AGONISTS AND METHODS THEREFOR |
| 04/09/2003 | EP1299385A2 Fused cyclic modulators of nuclear hormone receptor function |
| 04/09/2003 | EP1299383A1 Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders |
| 04/09/2003 | EP1299382A1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives |
| 04/09/2003 | EP1299365A1 2-aminothiazoline derivatives and their use as no-synthase inhibitors |
| 04/09/2003 | EP1299362A1 Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof |
| 04/09/2003 | EP1299355A2 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors |
| 04/09/2003 | EP1299351A1 Novel aryl, alkenyl, and alkynl 4-dedimethylaminotetracycline derivatives |
| 04/09/2003 | EP1299157A1 Composition and applicator for topical substance delivery |
| 04/09/2003 | EP1299125A1 Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| 04/09/2003 | EP1299103A1 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors |
| 04/09/2003 | EP1299090A1 Oral pharmaceutical composition with controlled release and prolonged absorption |
| 04/09/2003 | EP1299010A1 Vitamin k and essential fatty acids |
| 04/09/2003 | EP1230342A4 Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
| 04/09/2003 | EP1218021B1 Apple tree branch extracts for dermato-cosmetic use and method for preparing same |
| 04/09/2003 | EP1198453B1 N-(indolcarbonyl-)piperazin derivatives |
| 04/09/2003 | EP1150574A4 A natural tea for curing men's impotence and a method for manufacturing the same |
| 04/09/2003 | EP1094824A4 Prophylactic and therapeutic nutritional supplement for creation/maintenance of health-protective intestinal microflora and enhancement of the immune system |
| 04/09/2003 | EP1075191B1 Phytosterol compositions |
| 04/09/2003 | EP0963197A4 Guanylhydrazones useful for treating diseases associated with t cell activation |
| 04/09/2003 | EP0948320B1 PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF THE HMG-CoA REDUCTASE INHIBITOR FLUVASTATIN |
| 04/09/2003 | EP0912191B1 Vegetable extract, method for preparation thereof and its applications in human and veterinary medicine |
| 04/09/2003 | EP0906303B1 Ring-fused dihydropyranes, process for the preparation and use thereof |
| 04/09/2003 | EP0708768B1 Tri-substituted imidazoles having multiple therapeutic properties |
| 04/09/2003 | CN1409726A Type I cytokine receptor TCCR |
| 04/09/2003 | CN1409715A Cyclopenteneone derivatives |
| 04/09/2003 | CN1409712A Pyrrolo [2,3-d] pyrimidine compounds |
| 04/09/2003 | CN1409701A Crystalline form of (S)-2-ethoxy-3-[4-(2-{4-methane sulfonyloxy phenyl} ethoxy) phenyl] propanoic acid |
| 04/09/2003 | CN1409640A Polypeptide composition with improved stability |
| 04/09/2003 | CN1409639A TNF-alpha antagonist and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder |
| 04/09/2003 | CN1409632A Use of retigabin for treating neuropathic pain |
| 04/09/2003 | CN1408432A Calcium compensation capsule powder and its producing process |
| 04/09/2003 | CN1408428A Sugar cane free poly peptide calcium compensation powder and its producing method |
| 04/09/2003 | CN1408380A Medicine for curing diabetes |
| 04/09/2003 | CN1408371A Novel preparation of oyster calcium |
| 04/09/2003 | CN1408370A Novel compound preparation of oyster calcium (including calcium carbonate) and iron compensation agent |
| 04/09/2003 | CN1408364A Recipe composition of iron-compensation agent dry suspension |
| 04/09/2003 | CN1408363A Equalizing nutrient effervescent tablet and its preparing method |
| 04/09/2003 | CN1408352A Formula of iron-compensating agent chewing tablet |
| 04/09/2003 | CN1104897C Hesperidin and hesperetin as 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor |
| 04/09/2003 | CN1104896C RAR-gamma antagonist ligand or RAR-alpha agonist ligand as apoptosis inhibitor |
| 04/09/2003 | CN1104855C Composition and its use as food supplement or for lowering lipids in serum |
| 04/08/2003 | US6545155 Fused heteroaromatic glucokinase activators |
| 04/08/2003 | US6545150 Certain benzothiazine dioxide endothelin antagonists and processes for their preparation |
| 04/08/2003 | US6545137 Autoimmune diseases; antiinflammatory agents; viricides; antidiabetic agents; binding to low density lipoproteins |
| 04/08/2003 | US6545053 Aminoethoxyfluorene derivatives are beta-3 adrenaline receptor agonists and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc. |
| 04/08/2003 | US6545049 E.g., (2E, 4E, 6E)-7-(3,5-diisopropyl-2-n-heptyloxyphenyl)-3-methylocta-2,4,6-trienoic acid, esters or amides thereof |
| 04/08/2003 | US6545036 Potassium channel blockers; neuroprotectants, glaucoma, n-benzoyl indole compounds with 3-acylureamethyl group |